101 related articles for article (PubMed ID: 9147034)
1. Antiplatelet effects of R,S-(meso)-alpha, alpha'-bis[3-(N,N-diethylcarbamoyl) piperidino]-p-xylene ex vivo in the dog and in vivo in the mouse.
Han G; Bannerman D; Handa RK; Dillingham EO; Lawrence WH; Gollamudi R
Gen Pharmacol; 1997 Apr; 28(4):617-21. PubMed ID: 9147034
[TBL] [Abstract][Full Text] [Related]
2. Enantioselective antiplatelet actions of nipecotamides.
Gollamudi R; Feng Z; Dillingham EO; Bond SE; Han G; Salgia S
Thromb Res; 1993 Feb; 69(4):361-7. PubMed ID: 8470057
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic nipecotamide increases cyclic AMP levels and inhibits protein phosphorylation in human platelets.
Handa RK; Dillingham EO; Gollamudi R
Life Sci; 1995; 57(10):983-8. PubMed ID: 7643723
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of the novel antiplatelet agent alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide.
Lyman BA; Bond SE; Dillingham EO; Lawrence WH; Gollamudi R
Res Commun Chem Pathol Pharmacol; 1992 Dec; 78(3):279-88. PubMed ID: 1475529
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PAF-induced human platelet aggregation by antithrombotic nipecotomides.
Herron D; Dillingham EO; Lyman BA; Zheng X; Bond SE; Salgia SR; Gollamudi R
Prostaglandins Leukot Essent Fatty Acids; 1995 May; 52(5):309-18. PubMed ID: 7630919
[TBL] [Abstract][Full Text] [Related]
6. Preliminary in vivo studies on the platelet aggregation inhibitory activity of alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide in beagle dogs.
Lawrence WH; Gollamudi R; Dillingham EO; Carter-Burks G; Tisdelle PA; Lasslo A
J Pharm Sci; 1988 May; 77(5):464-5. PubMed ID: 3411473
[No Abstract] [Full Text] [Related]
7. The effect of alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene on human blood platelet structural physiology.
Lasslo A; White JG
Biochim Biophys Acta; 1984 Oct; 777(1):37-40. PubMed ID: 6435673
[TBL] [Abstract][Full Text] [Related]
8. Cytosolic ionized calcium in human platelets: the influence of collagen and a novel antiplatelet agent.
Gollamudi R; Dillingham EO; Bond SE; Lyman BA
Biochem Biophys Res Commun; 1991 Jun; 177(2):888-93. PubMed ID: 2049109
[TBL] [Abstract][Full Text] [Related]
9. Chiral resolution of alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene, a novel antiplatelet compound.
Gollamudi R; Feng ZX
Chirality; 1991; 3(6):480-3. PubMed ID: 1812959
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet activity of nipecotamides in experimental thrombosis in mice.
Lawrence WH; Howell RD; Gollamudi R
J Pharm Sci; 1994 Feb; 83(2):222-5. PubMed ID: 8169794
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of thrombus formation in vivo by novel antiplatelet agent.
Marzec UM; Kelly AB; Hanson SR; Lasslo A; Harker LA
Arteriosclerosis; 1990; 10(3):367-71. PubMed ID: 2140503
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of stereoisomers of antithrombotic nipecotamides.
Zheng X; Day C; Gollamudi R
Chirality; 1995; 7(2):90-5. PubMed ID: 7742174
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antiplatelet effects of a nipecotamide A-1C and low dose aspirin.
Han G; Bond SE; Lawrence WH; Dillingham EO; Zheng X; Gollamudi R
Gen Pharmacol; 1994 Nov; 25(7):1373-9. PubMed ID: 7896048
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of the platelet aggregation inhibitory activity of carbamoylpiperidines.
Feng Z; Gollamudi R; Dillingham EO; Bond SE; Lyman BA; Purcell WP; Hill RJ; Korfmacher WA
J Med Chem; 1992 Aug; 35(16):2952-8. PubMed ID: 1501222
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of piperidine-3-carboxamides as human platelet aggregation inhibitors.
Zheng X; Salgia SR; Thompson WB; Dillingham EO; Bond SE; Feng Z; Prasad KR; Gollamudi R
J Med Chem; 1995 Jan; 38(1):180-8. PubMed ID: 7837229
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet effects of caffeic acid due to Ca(2＋) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation.
Lee DH; Kim HH; Cho HJ; Bae JS; Yu YB; Park HJ
J Atheroscler Thromb; 2014; 21(1):23-37. PubMed ID: 24088646
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet activity of Phellinus baummii methanol extract is mediated by cyclic AMP elevation and inhibition of collagen-activated integrin-α(IIb) β₃ and MAP kinase.
Kamruzzaman SM; Endale M; Oh WJ; Park SC; Kim TH; Lee IK; Cho JY; Park HJ; Kim SK; Yun BS; Rhee MH
Phytother Res; 2011 Nov; 25(11):1596-603. PubMed ID: 21394810
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet mechanism of an herbal mixture prepared from the extracts of Phyllostachys pubescens leaves and Prunus mume fruits.
Son E; Kim SH; Yang WK; Kim DS; Cha J
BMC Complement Altern Med; 2017 Dec; 17(1):541. PubMed ID: 29258493
[TBL] [Abstract][Full Text] [Related]
19. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet agents affecting the interaction of Tissue Factor-Factor VIIa complex with Factor X in a continuous-flow reactor.
Gir S; Reavis R; Turitto VT; Gollamudi R
Biotechnol Appl Biochem; 1996 Feb; 23(1):63-6. PubMed ID: 8867897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
